Induction of luteolysis by luteinizing hormone-releasing factor (LRF) agonist: sensitivity, reproducibility, and reversibility.
The reproducibility, reversibility, and the maximal effectiveness of the luteolytic action of [D-Trp6,Pro9NEt]-LRF (luteinizing hormone-releasing factor) (LRF-agonist) were evaluated during 43 treatment cycles in 15 normal women. LRF-Ag (50 microgram) administration subcutaneously on 1 or 2 days at varying times during the luteal phase of consecutive cycles was made. Successful luteolysis was achieved in 26 of 27 cycles (96%) in which LRF-Ag was administered between 5 and 8 days after the luteinizing hormone (LH) peak. However, LRF-Ag treatment failed to induce luteolysis in 10 of 13 cycles (77%) when treatment began within 5 days of the LH peak. The luteal phase of posttreatment cycles was functionally unaffected by prior LRF-Ag treatment. The present study has thus demonstrated the reproducibility and reversibility of LRF-Ag as a potent luteolytic agent, although its action is dependent upon the timing of administration with a window of maximal effectiveness on days 5 to 8 of the luteal phase.
D000328:Adult; D003338:Corpus Luteum / Q000187:drug effects*; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008186:Luteolytic Agents / Q000494:pharmacology*; D011374:Progesterone / Q000097:blood; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives*
D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; C019176:Tryptal; D007986:Luteinizing Hormone